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Abstract
 
CD4
 
 
 
CD25
 
 
 
 regulatory T cells inhibit organ-specific autoimmune diseases induced by
CD4
 
 
 
CD25
 
  
 
T cells and are potent suppressors of T cell activation in vitro. Their mechanism
of suppression remains unknown, but most in vitro studies suggest that it is cell contact–depen-
dent and cytokine independent. The role of TGF-
 
 
 
1 in CD4
 
 
 
CD25
 
  
 
suppressor function re-
mains unclear. While most studies have failed to reverse suppression with anti–transforming
growth factor (TGF)-
 
 
 
1 in vitro, one recent study has reported that CD4
 
 
 
CD25
 
 
 
 T cells ex-
press cell surface TGF-
 
 
 
1 and that suppression can be completely abrogated by high concentra-
tions of anti–TGF-
 
 
 
 suggesting that cell-associated TGF-
 
 
 
1 was the primary effector of
CD4
 
 
 
CD25
 
 
 
-mediated suppression. Here, we have reevaluated the role of TGF-
 
 
 
1 in
CD4
 
 
 
CD25
 
 
 
-mediated suppression. Neutralization of TGF-
 
 
 
1 with either monoclonal anti-
body (mAb) or soluble TGF-
 
 
 
RII-Fc did not reverse in vitro suppression mediated by resting
or activated CD4
 
 
 
CD25
 
 
 
 T cells. Responder T cells from Smad3
 
 
 
/
 
 
 
 or dominant-negative
TGF-
 
 
 
 type RII transgenic (DNRIITg) mice, that are both unresponsive to TGF-
 
 
 
1–induced
growth arrest, were as susceptible to CD4
 
 
 
CD25
 
 
 
-mediated suppression as T cells from wild-
type mice. Furthermore, CD4
 
 
 
CD25
 
 
 
 T cells from neonatal TGF-
 
 
 
1
 
 
 
/
 
 
 
 mice were as
suppressive as CD4
 
 
 
CD25
 
 
 
 from TGF-
 
 
 
1
 
 
 
/
 
 
 
 mice. Collectively, these results demonstrate
that CD4
 
 
 
CD25
 
 
 
 suppressor function can occur independently of TGF-
 
 
 
1.
 
Key words: CD4
 
 
 
 suppressor T cells • autoimmunity • tolerance • immunoregulation • 
IL-2 receptor
 
Introduction
 
Although clonal deletion of autoreactive T cells in the thy-
mus and the induction of T cell anergy in the periphery are
the major mechanisms responsible for T cell tolerance, the
ability to detect autoreactive T cells in normal individuals
strongly suggests that neither of these mechanisms is fail-
safe and that additional mechanisms of dominant immune
tolerance must exist (1–3). Studies in a number of experi-
mental animal models have demonstrated the existence of
regulatory T cell populations that prevent the activation of
autoreactive T cells (4). CD4
 
 
 
CD25
 
 
 
 T cells represent one
of the best characterized populations of regulatory T cells
and prevent the development of autoimmune disease that
occurs after day 3 thymectomy, the transfer of disease me-
diated by autoreactive T cell clones, as well as disease in-
duced by CD4
 
 
 
 T cell populations that are depleted of reg-
ulatory T cells (e.g., CD4
 
 
 
CD25
 
  
 
or the CD4
 
 
 
CD45RB
 
high
 
subsets; references 5 and 6). Furthermore, a partial defi-
ciency of CD4
 
 
 
CD25
 
 
 
 T cells may also contribute to the
genetic susceptibility of autoimmunity as seen in NOD
mice, which spontaneously develop insulin-dependent
diabetes mellitus (7). CD4
 
 
 
CD25
 
 
 
 T cells suppress CD4
 
 
 
CD25
 
  
 
or CD8
 
 
 
 T cell proliferation and cytokine produc-
tion (IL-2 and IFN-
 
 
 
) in vitro (8, 9). However, the mech-
anism by which CD4
 
 
 
CD25
 
 
 
 T cells mediate their sup-
pressive effects is poorly understood. In most studies,
suppression is cell contact dependent and not mediated by
IL-4 or IL-10 as CD4
 
 
 
CD25
 
 
 
 T cells from IL-4–deficient
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CD4
 
 
 
CD25
 
 
 
 Regulatory T Cells and TGF-
 
 
 
(
 
 
 
/
 
 
 
) and IL-10
 
 
 
/
 
 
 
 mice are as effective as CD4
 
 
 
CD25
 
 
 
 T
cells from wild-type (WT)
 
*
 
 mice in vitro and in mediating
suppression of autoimmune gastritis (AIG) in vivo (8, 10).
TGF-
 
 
 
1 plays an important role in maintaining im-
mune homeostasis in general, and in regulating T cells, in
particular. Global disruption of the TGF-
 
 
 
1 gene in mice
has clearly illustrated the importance of this specific
TGF-
 
 
 
 isoform in regulating immune cell differentiation
and function. TGF-
 
 
 
1
 
 
 
/
 
 
 
 mice manifest a spontaneous
autoimmune-like syndrome, with aberrant expression of
MHC class I and II antigens, circulating SLE-like IgG an-
tibodies to nuclear antigens, pathogenic glomerular IgG
deposits, and a progressive infiltration of mononuclear cells
into multiple organs (11–15). This syndrome can be adop-
tively transferred to lethally irradiated TGF-
 
 
 
1
 
 
 
/
 
 
 
 recipi-
ents with TGF-
 
 
 
1
 
 
 
/
 
 
 
 bone marrow, suggesting an impor-
tant role for autocrine production of TGF-
 
 
 
1 in immune
cells. The importance of T cells in the genesis of this syn-
drome is supported by the observation that T cell–specific
disruption of TGF-
 
 
 
 signaling leads to a similar, though
less aggressive syndrome (16–19). In this model, T cell–
specific expression of a dominant-negative TGF-
 
 
 
 type
RII transgenic (DNRIITg) results in spontaneous activa-
tion of T cells, lymphocyte infiltration into multiple or-
gans, and autoantibody production. Specific intracellular
intermediates that regulate these responses have also been
globally disrupted in mice, including the genes encoding
Smad2 and Smad3 (14, 18). Loss of 
 
Smad3
 
 has been associ-
ated with chemotaxis defects, altered T cell responses to
TGF-
 
 
 
, and invasive mucosal infection with typically
nonpathogenic microorganisms.
Overall, these in vivo models support the importance of
TGF-
 
 
 
 in maintaining immune homeostasis, and raise the
possibility that TGF-
 
 
 
 may play a critical role in immune
suppression mediated by CD4
 
 
 
CD25
 
 
 
 suppressor T cells.
Neutralizing antibodies to TGF-
 
 
 
 have been shown to re-
verse suppression mediated by regulatory T cells (enriched
in CD25
 
 
 
 T cells) of inflammatory bowel disease (IBD) in
mice (20) and thyroiditis (21) in rats. However, the cellular
source and specific isoform of the TGF-
 
 
 
 was not ad-
dressed in these studies but was assumed to be TGF-
 
 
 
1 de-
rived from the regulatory T cells. Considerable controversy
exists on the role TGF-
 
 
 
1 plays in the induction and exe-
cution of CD4
 
 
 
CD25
 
 
 
-mediated suppressor function in
vitro. Most studies have concluded that suppression is not
mediated by secreted TGF-
 
 
 
1 because of the requirement
for cell contact and the failure to reverse suppression with
anti–TGF-
 
 
 
1 in murine (8, 22, 23) as well as human sys-
tems (24–29). Nakamura et al. have recently proposed a
novel model in which CD4
 
 
 
CD25
 
 
 
 T cells express cell
surface latent TGF-
 
 
 
1 and mediate suppression via a cell
contact–dependent presentation/activation of latent TGF-
 
 
 
1 to a TGF-
 
 
 
R on target CD4
 
 
 
CD25
 
  
 
T cells (30). This
conclusion was based on the ability to detect the expression
of cell surface TGF-
 
 1 by flow cytometry and to com-
pletely abrogate suppression with high concentrations of
anti–TGF- . However, this study did not conclusively
show functional evidence for a direct effect of TGF- 1 on
responder T cells, nor did it consider the possibility that
cell surface TGF- 1 mediated its effects by acting on the
CD4 CD25  suppressor T cells.
In this paper, we have taken advantage of the genetic
models described above to critically evaluate whether
CD4 CD25 -mediated suppression of T cell activation is
dependent on the ability of CD4 CD25  to produce
TGF- 1 or on the ability of target T cells to respond to
TGF- 1. Neutralization of TGF- 1 with either mAb or
soluble TGF- RII-Fc chimera did not reverse in vitro sup-
pression mediated by resting or activated CD4 CD25  T
cells. Then, we demonstrate that both CD4  and CD8 
responder T cells from Smad3 /  and DNRIITg mice,
while unresponsive to exogenous rhTGF- 1, are as suscep-
tible to suppression by CD4 CD25  T cells as WT T cells.
Furthermore, we demonstrate that CD4 CD25  T cells
isolated from neonatal TGF- 1 /  mice are as effective as
CD4 CD25  T cells from WT mice in their capacity to
suppress proliferative responses of T cells from WT mice.
Finally, we show that neutralization of TGF- 1 in vivo did
not abrogate CD4 CD25 -mediated protection of AIG.
These results formally demonstrate that CD4 CD25  sup-
pressor activity can occur in the functional absence of
TGF- 1 production or responsiveness.
Materials and Methods
Mice. TGF- 1 /  and Smad3 /  mice (C57BL/6 Sv129)
were generated by targeted gene disruption in murine embryonic
stem cells by homologous recombination (18, 31). Control litter-
mates were bred and maintained in a pathogen-free animal facil-
ity. Female C57BL/6 and BALB/c mice were obtained from the
National Cancer Institute. DNRIITg mice (C57BL/6 genetic
background) were provided by Philip Lucas (National Cancer In-
stitute, National Institutes of Health). Unless specified, the mice
used in these experiments were 6–8 wk of age.
 Reagents. Human rIL-2 was purchased from Peprotech. Hu-
man rTGF- 1 was obtained from R&D Systems. The following
antibodies were used for in vitro stimulation/neutralization and
flow cytometry experiments: biotin anti-CD25 (7D4 clone); PE-
CD25 (PC61 clone); PE-streptavidin; PE anti-CD4; PE anti-
CD8; PE anti-CD69; and purified anti-CD3  (2C11) were pur-
chase from BD PharMingen. Tricolor CD4 was purchased from
Caltag Laboratories. Anti–TGF-  antibodies (clones 1D11,
9016.2, and R&D Systems model AB-101-NA) and soluble
TGF- RII-Fc were purchased from R&D Systems.
Cell Purification. CD4 CD25  T cells were isolated on a
FACStar™ Cell Sorter. In brief, fresh lymph nodes (axillary, in-
guinal, brachial, and mesenteric) were collected from adult
BALB/c, C57BL/6, or appropriate knockout mice and single cell
suspensions were prepared by passing cells through a sterile wire
mesh. Cells were resuspended in HBSS/5% FCS, gently layered
on a Lympholyte-M gradient (Cederlane), and centrifuged ac-
cording to the manufacturer’s specifications to remove dead cells.
The resulting cell preparation was stained with biotin-conjugated
anti-CD25 (15  g/108 cells) in PBS/2% FCS for 20 min at 4 C,
*Abbreviations used in this paper: AIG, autoimmune gastritis; DNRIITg,
dominant-negative TGF-  type RII transgenic; IBD, inflammatory
bowel disease; WT, wild-type.239 Piccirillo et al.
washed, and then incubated with PE-streptavidin (15  g/108
cells) and Tricolor-CD4 (15  g/108 cells) in PBS/2% FCS for 20
min at 4 C. The cells were then washed and resuspended in
RPMI 1640/10% FCS (no phenol red) for FACS® sorting. The
purity of the final CD4 CD25  preparation was typically  98%.
T cell–depleted spleen cells were used as APC and were prepared
by lysing the RBCs with ACK lysing buffer, followed by nega-
tive selection (depletion of T cells with Thy1.2 magnetic beads)
on the AutoMACS® magnetic separation system according to the
manufacturer’s protocol. The cells were then washed extensively
and irradiated at 3,000 rads. CD4  and CD8  responder T cells
were prepared from spleens or lymph node of appropriate adult
mice. Single cell suspensions were prepared as described above,
and responder T cells were purified by either negative (depletion
of B220 , CD4, or CD8 and I-Ab-positive cells) or positive se-
lection (using CD4 or CD8 magnetic beads) on the AutoMACS®
magnetic separation system. In some experiments, cells were la-
beled with CFSE as described previously (32).
Proliferation Assays. Proliferation assays were performed by
culturing CD4  or CD8  T cells (5   104) in 96-well, flat-bot-
tomed microtiter plates (0.2 ml) in RPMI 1640 (Biofluids) sup-
plemented with 10% heat-inactivated FCS, penicillin (100
U/ml), streptomycin (100  g/ml), 2 mM L-glutamine, 10 mM
Hepes, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate
(all obtained from Biofluids) and 50  M 2-ME (Sigma-Aldrich)
with irradiated, T cell–depleted spleen cells (1–2   105 cells) for
72 h at 37 C in 7% CO2. Cell cultures were pulsed with 1  Ci
3[H]TdR for the last 6–12 h. All the data represents the average
counts per minute of triplicate determinations. All proliferation
experiments were repeated at least three times.
To generate CD4 CD25  short-term cell lines, cell sorted
CD4 CD25  cells were cultured with irradiated APC (1:1), 0.5
 g/ml anti-CD3 and 5 ng/ml (100 U/ml) hIL-2 for 72 h and
were then split and maintained in IL-2 media for  5–7 d. In
some experiments, CD4 CD25  cells were prepared by stimula-
tion with plate-bound anti-CD3 (5 ug/ml) and IL-2 (5 ng/ml)
for 72 h.
 Flow Cytometry.  Cells were collected and stained with PE-
CD4, PE-CD8, FITC-CD69, or FITC-CD25 and analyzed with
FACScan™ flow cytometer (Becton Dickinson) using the
CELLQuest™ software program.
Induction and Suppression of AIG. CD4 CD25  T cells were
depleted from BALB/c mice by treatment with anti-CD25
(PC61, 1 mg, intraperitoneally) every other day beginning on day
10 of life. Splenocytes from the depleted mice were harvested on
day 24 and injected (20   106 cells) intravenously into BALB/c
nu/nu or C.B-17 SCID mice. Some animals were coinjected
with splenocytes (50   106) from normal BALB/c mice. One
group of recipients was treated with anti–TGF-  (1D11.16, 2 mg
intraperitoneally, on days –1 and 1 of cell transfer and weekly
thereafter for 6 wk). Gastric pathology was evaluated as described
previously (33) using disease scores ranging from normal gastric
mucosa (0) to severe gastritis (6).
Results
Anti–TGF- 1 Antibodies and Soluble TGF- RII-Fc Fail
To Reverse Suppression Mediated by Resting or Activated
CD4 CD25  T Cells. We and others (8, 22, 23) have
previously demonstrated that TGF- 1 mAbs (10  g/ml)
failed to reverse suppression mediated by freshly isolated
CD4 CD25  T cells. Nakamura et al. (30) demonstrated
that suppression could only be reversed with higher con-
centrations ( 25  g/ml) of anti–TGF- 1 and suggested
that the higher concentration was needed to penetrate the
physical interaction of the responder T cells with the sup-
pressor T cell–bearing surface latent TGF- 1. We did not
observe reversal of suppression of T cell responses to solu-
ble anti-CD3 and APC even in the presence of high con-
centrations of anti–TGF- 1 (Fig. 1). We previously dem-
onstrated that activated CD4 CD25  cells maintain their
anergic phenotype and exhibit enhanced suppressor func-
tion in the absence of TCR reengagement (34). Naka-
mura et al. have demonstrated that activated CD4 
CD25  T cells express high levels of membrane-bound la-
tent TGF- 1 complexes and have hypothesized that this
would account for the enhanced antigen nonspecific sup-
pressive capacity of activated CD4 CD25  T cells. How-
ever, suppression mediated by activated CD4 CD25  T
cells was readily observed even in the presence of high
Figure 1. TGF- 1 blockade does not reverse CD4 CD25 -mediated
suppression of T cell proliferation. (A) WT CD4  T cells (5   104) were
stimulated with irradiated T cell–depleted spleen cells (2   105) either
alone or with freshly isolated or activated ( ) CD4 CD25  T cells (1:2
suppressor/responder ratio) in the presence of titrated doses of anti–TGF- 1.
Results from a representative experiment of three are shown. (B) OT-I
Tg CD8  T cells were stimulated with H-2Kb/OVA257–264 soluble tet-
ramer (0.1  g/ml) either alone or with activated CD4 CD25  T cells
(1:2 suppressor/responder ratio) in the presence or absence of soluble
TGF- RII-Fc (10  g/ml). In some instances, rhTGF- 1 was added as a
control (5 ng/ml).240 CD4 CD25  Regulatory T Cells and TGF- 
concentrations of anti–TGF-  (50  g/ml) (Fig. 1 A). The
inability to reverse suppression was also observed when
the TCR signal strength was increased 20-fold (Fig. 1 A)
demonstrating that the failure to abrogate suppression
could not be explained by suboptimal T cell activation.
Identical results were observed when activated CD4 
CD25  T cells were mixed with CD4  T cells from TCR
Tg mice that were stimulated with specific peptide and
APC under conditions where the activated suppressor cells
were not restimulated in the assay culture (unpublished
data). In some experiments, antibodies directed at all
TGF-  isoforms or antibodies directed at latent TGF- 1
were used with identical results (unpublished data). Simi-
lar results were obtained using limiting numbers of acti-
vated suppressors in order to maximize the capacity of
high dose anti–TGF- 1 to reverse suppression (unpub-
lished data).
Activated CD4 CD25 -mediate suppression of anti-
gen-specific CD8  T cell activation in an APC-free
manner when the CD8  T cells are stimulated with pep-
tide-MHC class I tetramers (9). To further evaluate the
potential role of TGF- 1 in the suppression of T cell acti-
vation, we stimulated CD8  T cells from OT-I mice with
soluble H-2Kb/OVA257–264 tetramers, in the presence of
activated CD4 CD25  T cells, and either in the presence
or absence of saturating doses of sTGF- RII-Fc, a natural
competitor of TGF- 1. The sTGF- RII-Fc reagent is ca-
pable of binding various isoforms, including TGF- 1,
with sufficient affinity to act as a potent inhibitor of TGF-
 1 activity. When OT-I Tg CD8  T cells were stimu-
lated with tetramer in the presence of activated
CD4 CD25  T cells, marked suppression of proliferation
was observed at a suppressor/responder ratio of 1:2
( 65%) (Fig. 1 B). Interestingly, suppression was not ab-
rogated in the presence of a concentration of sTGF- RII-
Fc (10  g/ml) that was capable of inhibiting the sup-
pressive effects of rTGF- 1 (5 ng/ml) on CD8  T cell
proliferation (Fig. 1 B). In summary, in vitro blockade of
TGF- 1 by means of neutralizing antibodies or sTGF-
 RII-Fc had no effect on suppression mediated by resting
or activated CD4 CD25 T cells in APC-dependent and
-independent systems.
CD4  T Cells from Smad3 /  or DNRIITg Mice Are Sus-
ceptible To Suppression Mediated by CD4 CD25  T Cells
while Resistant to the Antiproliferative Effects of TGF- 1. In
an attempt to further evaluate the effector role of TGF- 1
in CD4 CD25 -mediated suppression, we made use of
genetic models characterized by TGF- 1 unresponsiveness
in T cells. Targeted disruption of the Smad3 gene resulted
in the complete loss of sensitivity to TGF- 1 growth inhi-
bition in T cells (18). More importantly, the ability of
TGF- 1 to suppress T cell proliferation and IL-2 gene
transcription depends on the successful activation of Smad3
pathway (35). If CD4 CD25 -mediated suppression re-
quires TGF- 1, then CD4 CD25  T cells would not sup-
press CD4  T cells from Smad3 /  mice. When stimulated
with soluble anti-CD3, CD4  T cells from Smad3 /  mice
were completely resistant to the antiproliferative effects of
exogenous rhTGF- 1 (Fig. 2 A), while the proliferation of
WT CD4  T cells was strongly inhibited (Fig. 2 A). More
importantly, CD4  T cells from Smad3 /  mice were as
susceptible to suppression mediated by CD4 CD25  T
cells from WT mice as CD4 CD25  T cells from WT
mice (Fig. 2 B). These results suggest that CD4 CD25 -
mediated suppression does not occur via a Smad3-depen-
dent TGF-  signaling pathway in target CD4  T cells.
Smad3-dependent signaling in CD4 CD25  T cells was
also not an essential requirement for suppressor function as
CD4 CD25  T cells from Smad3 /  were as efficient in
mediating suppression as CD4 CD25  T cells from WT
mice (Fig. 2 C).
To rule out the possibility that CD4 CD25  T cells
may exert a TGF- 1–dependent effect, which does not re-
quire signaling via Smad3, we also tested the susceptibility
of CD4  T cells from a transgenic mouse that overex-
Figure 2. CD4  T cells from TGF- 1–insensitive Smad3 /  mice are
susceptible to suppression mediated by CD4 CD25  T cells. (A) WT or
Smad3 /  CD4  T cells (5   104) were stimulated with anti-CD3 (0.5
 g/ml) and irradiated, T cell–depleted spleen cells (2   105) in the pres-
ence or absence of exogenous rhTGF- 1. (B) WT or Smad3 /  CD4  T
cells (5   104) were stimulated as described in A in the presence of ti-
trated numbers of either activated CD4 CD25  or CD4 CD25  T cells.
(C) Smad3-dependent signaling in CD4 CD25  T cells is not required
for suppressor effector function. WT CD4  T cells were stimulated as de-
scribed in A and in the presence of either freshly isolated CD4 CD25  or
CD4 CD25  T cells from WT or Smad3 /  mice. The final purity of
sorted suppressors was  98%.241 Piccirillo et al.
presses a dominant-negative form of the TGF-  type II re-
ceptor in T cells (17). Both CD4  and CD8  T cells from
DNRIITg mice were markedly resistant to the antiprolifer-
ative effects of exogenous rhTGF- 1 (Fig. 3 A), while both
populations remained susceptible to CD4 CD25 -medi-
ated suppression (Fig. 3 B). Taken together, these results
strongly suggest that CD4 CD25 -mediated suppression
can occur without functional TGF- 1–induced signaling
in responding T cells.
CD4 CD25  T Cells from TGF- 1 /  Mice Function
Normally.  The most direct approach for the assessment of
TGF- 1 function in CD4 CD25 -mediated suppression is
the evaluation of the suppressor function of CD4 CD25 
T cells from TGF- 1 /  mice. As these mice rapidly de-
velop an autoimmune phenotype by 3–4 wk of age (13),
we isolated CD4 CD25  T cells from 5–7-d old mice. At
this age, the mice were phenotypically normal and demon-
strated no visible sign of disease. Furthermore, analysis of
activation marker expression on total CD4  and CD8  T
cells, as well as CD4 CD25  T cells from these mice re-
vealed expression patterns indistinguishable from those seen
in control WT littermates (unpublished data). Moreover,
the frequency of CD4 CD25  T cells was comparable be-
tween WT and TGF- 1 /  neonatal mice, comprising
 8% of total CD4  T cells (Fig. 4 A). CD4 CD25  T
cells from TGF- 1 /  mice resembled CD4 CD25  T
cells from WT mice as they did not proliferate spontane-
ously (unpublished data), were nonresponsive when stimu-
lated via their TCR, but proliferated vigorously in the
presence of anti-CD3 and exogenous IL-2 (Fig. 4 B). This
was strongly suggestive that the CD4 CD25  T cells
present in neonatal TGF- 1 /  were not derived from a
preactivated effector T cell pool. More importantly,
CD4 CD25  T cells from TGF- 1 /  neonatal mice
were as efficient as CD4 CD25  T cells from WT mice in
mediating suppression of the response of WT CD4  T cells
to anti-CD3 stimulation (Fig. 4 C).
As TCR-induced proliferation of CD4  T cells from
normal mice is enhanced in the absence of CD4 CD25  T
cells in vitro (4, 36), we next evaluated whether depletion
of CD4 CD25  T cells from lymphoid populations de-
rived from TGF-  /  mice also resulted in enhanced pro-
liferation. Therefore, we first depleted CD25  T cells from
either WT (Fig. 5 A) or TGF- 1 /  lymphoid cells from
neonatal mice (Fig. 5 B), stimulated the depleted popula-
tion with soluble anti-CD3, and examined the frequency
of dividing cells based on CFSE dilution by flow cytome-
try. As shown in Fig. 5 A, the number of cell divisions and
the frequency of dividing CD4  and CD8  T cells in-
creases in an identical fashion when CD25  T cells are re-
moved from WT and TGF- 1 /  lymphoid cells. In addi-
tion, when CD25-depleted TGF- 1 /  populations were
reconstituted with nondepleted TGF- 1 /  cells, the pro-
liferative response was similar to that seen in nondepleted
controls (Fig. 5 C). This result clearly suggests that
CD25  T cell regulatory activity is normal in neonatal
TGF- 1 /  lymphoid tissues and that solely a deficiency of
CD4 CD25  T cells does not establish autoimmunity in
TGF- 1 /  mice.
Figure 3. CD4 CD25  T cells suppress T cells from DNRIITg mice.
(A) T cells from WT or DNRIITg mice (5   104 cells) were stimulated
with anti-CD3 (0.5  g/ml) and irradiated, T cell–depleted spleen cells
(2   105) in the presence or absence of exogenous rhTGF- 1. (B) CD4 
or CD8  T cells (5   104) from WT or DNRIITg mice were stimulated
as described in A in the presence or absence of either activated
CD4 CD25  or CD4 CD25  T cells.
Figure 4. CD4 CD25  regu-
latory T cell activity is operative
in TGF- 1 /  mice. (A) The
frequency of CD4 CD25  T
cells is comparable in WT and
TGF- 1 /  neonatal mice. (B)
WT or TGF- 1 /  CD4 
CD25  or CD4 CD25  T cells
(5   104) were stimulated with
anti-CD3 (0.5  g/ml) and irra-
diated, T cell–depleted spleen
cells (2   105) in the presence or
absence of exogenous IL-2 (5
ng/ml). (C) WT CD4  T cells
were stimulated as described in B
in the presence of either freshly
isolated CD4 CD25  or CD4 
CD25   T cells from WT or
TGF- 1 /  neonatal mice.242 CD4 CD25  Regulatory T Cells and TGF- 
Anti–TGF-  Does Not Abrogate CD4 CD25 -mediated
Suppression of AIG. To evaluate the potential involve-
ment of TGF- 1 in CD4 CD25 -mediated suppression
of autoimmunity in vivo, we transferred CD4 CD25  T
cells to nu/nu recipients. After 6–8 wk, all animals mani-
fested pathologic changes consistent with severe AIG (Fig.
6). When spleen cells from normal BALB/c donors con-
taining CD4 CD25  T cells were cotransferred with the
CD4 CD25  T cells, marked suppression of disease was
observed. Anti–TGF- 1 did not enhance disease severity
when given to recipients of CD4 CD25  effectors, nor
did it reverse the suppression mediated by the CD4 
CD25  population.
Discussion
Over the past 10 y a number of regulatory CD4  T cell
populations capable of inhibiting immune responses both
in vivo and in vitro have been described previously (2, 4,
37, 38). Some of the immunosuppressive effects of these
regulatory T cells appear to be mediated by secretion of
suppressor cytokines such as IL-4, IL-10, and TGF- 1.
CD4 CD25  T cells in mouse and man represent a popu-
lation of naturally occurring professional suppressor T cells
whose inhibitory effects have been studied by a number of
groups. It is widely accepted that this population of sup-
pressor cells mediates its function in vitro by a direct cell
contact–dependent mechanism that is independent of the
above-mentioned secreted suppressor cytokines (5, 39).
Nakamura et al. (30) have recently offered an alternative
hypothesis by demonstrating that activated CD4 CD25  T
cells secrete latent TGF- 1 that is subsequently bound to
their surface. Membrane-bound latent TGF- 1 is then de-
livered to responder CD4 CD25  T cells on whose surface
latent TGF- 1 would be activated and bound to TGF-
 RII with resultant delivery of a suppressive signal for T
cell activation. In light of the critical role of TGF- 1 in
regulating T cell responses (40), the major goal of the
present study was to reexplore the potential involvement of
TGF- 1 in suppressor T cell effector function. To achieve
this, we have made use of several genetic model systems in
which CD4 CD25  T cell suppressor function can be as-
sessed in vitro in the complete absence of suppressor-
derived TGF- 1 production and target T cell responsive-
Figure 5. In vitro depletion of CD4 CD25  regulatory T cell activity
in TGF- 1 /  mice enhances T cell proliferation. CD25-depleted or
nondepleted splenocytes/lymph node cells from either WT (A) or
TGF- 1 /  (B) neonatal mice were labeled with CFSE and stimulated
with anti-CD3 (0.5  g/ml) and irradiated, T cell–depleted spleen cells
(2   105) for a period of 48 h. Cells were then analyzed by flow cytome-
try for CFSE division status relative to unstimulated T cells (solid yellow
line). All histograms were gated on CD4  or CD8  T cells. (C) CD25-
depleted WT or TGF- 1 /  cells were reconstituted with the respective
nondepleted cell preparation, stimulated with soluble anti-CD3, and then
examined the frequency of dividing cells based on CFSE dilution by flow
cytometry. Cells were gated on CD4  T cells.
Figure 6.  Anti–TGF-  does not reverse suppression of AIG mediated
by CD4 CD25  T cells. Nu/nu mice (6–8 wk) were injected with sple-
nocytes depleted of CD25  cells (20   106 cells), as described in the Ma-
terials and Methods. Simultaneously, some nu/nu mice were coinjected
with CD4 CD25  T cells (2   106 cells). Anti–TGF-  (2 mg) was in-
jected on days –1 and 1 of cell transfer and weekly thereafter for the dura-
tion of the experiment. Stomachs were harvested 6 wk after transfer and
H&E stains of formalin-fixed, paraffin-embedded sections were analyzed
for gastric pathology.243 Piccirillo et al.
ness to TGF- 1. Collectively, our studies demonstrate that
CD4 CD25 -mediated T cell suppression can occur inde-
pendently of TGF- 1 production and responsiveness in
vitro and for suppression of AIG in vivo.
We have been unable to confirm the observations of
Nakamura et al. (30) that suppression of anti-CD3 medi-
ated activation by freshly explanted CD4 CD25  could be
reversed by high concentrations of anti–TGF- 1. More
importantly, we did not observe any effects of either anti–
TGF- 1 antibodies or sTGF- RII-Fc on the immunosup-
pressive effects of activated CD4 CD25  T cells. We have
previously shown that the latter population has enhanced
suppressor function and also mediates antigen nonspecific
suppression in the absence of reengagement of their TCR.
Activated CD4 CD25  T cells were shown by Nakamura
et al. (30) to be highly reactive with an anti–rhTGF- 1
polyclonal chicken antibody as measured by flow cytome-
try and therefore should have been readily susceptible to
inhibition by anti–TGF- 1. We also have been unable to
consistently observe significant differences in the expression
of cell surface TGF- 1 on activated CD4 CD25  T cells
when compared with similarly activated CD4 CD25  T
cells. Both activated populations stained very weakly al-
though in some studies the activated CD25  population
was marginally brighter (unpublished data). It should also
be pointed out that cell surface TGF- 1 could only be de-
tected with a polyclonal chicken anti-rhTGF- 1 serum
and studies demonstrating the specificity of the staining by
blocking with rhTGF- 1 were not reported. The reasons
for the discrepancy observed between these two studies are
unknown but may reflect technical differences in experi-
mental protocols.
It is always difficult to determine the mechanism of re-
versal of inhibition by adding a neutralizing antibody to a
complex mixture of cells that are both capable of produc-
ing and responding to the target cytokine. As an alterna-
tive approach, we used CD4 CD25  T cells that could
not produce TGF- 1 and CD4 CD25  T cells that could
not respond to TGF- 1-induced growth arrest. Activation
of CD4 CD25  T cells from the Smad3 /  and DNRI-
ITg mice was completely resistant to the immunosuppres-
sive effects of TGF- 1 yet T cells from each mouse model
were readily suppressed by CD4 CD25  T cells from WT
mice. We were also able to purify CD4 CD25  T cells
from TGF- 1 /  mice and demonstrate that they pheno-
typically and functionally resembled CD4 CD25  T cells
from WT mice. Importantly, they were as suppressive as
WT CD4 CD25  T cells when mixed with CD4 
CD25  T cells from WT mice. As the autoimmune syn-
drome seen in TGF- 1 /  mice is much more severe
than that seen in d3Tx mice that lack CD4 CD25  T
cells, it is likely that CD4 CD25 -mediated suppression,
although operative in young TGF- 1 /  mice, is over-
whelmed by other manifestations of a global deficiency in
TGF- 1. Collectively, these studies rule out the possibil-
ity that production of, or responsiveness to, TGF- 1 is
absolutely required for CD4 CD25 -mediated suppres-
sion in vitro.
Interpretation of the effects of anticytokine reagents on
the reversal of regulatory T cell mediated suppression of
autoimmune disease in vivo is also difficult. It has previ-
ously been reported that suppression of IBD induced by
transfer of CD4 CD45RBhigh T cells into SCID recipients
by cotransfer of regulatory CD4 CD45RBlow T cells can
be reversed by treatment of the recipient animals with anti–
TGF- 1 (20). CD4 CD45RClow T cell–mediated sup-
pression of thyroiditis in the rat was also reversed by anti–
TGF-  (21). Although both murine CD4 CD45RBlow T
cells and rat CD4 CD45RClow are highly enriched in
CD4 CD25  T cells, they also contain CD4 CD25  cells
that are derived from the memory/effector cell pool. The
cellular source(s) of the TGF- 1 that mediates inhibition of
autoimmune disease in these models is unknown and it
may be produced by members of the regulatory population
or even by host lymphoid or nonlymphoid cells, such as
gut epithelium. In the present report, suppression of
AIG induced by CD4 CD25  T cells by cotransfer of
CD4 CD25  T cells was not reversed by an anti–TGF- 
treatment protocol identical to that used to reverse sup-
pression of IBD. AIG also differs from IBD in that
CD4 CD25  T cells from IL-10 /  mice are capable of
mediating suppression (41). One major difference between
IBD and AIG is that intestinal bacteria play a major role in
the induction of disease (42) in the former, while AIG can
be readily induced in germ-free mice (43). The involve-
ment of IL-10 and TGF- 1 in suppression of IBD does not
rule out that cell contact mediated inhibition of effector
function is also operative. IL-10 and TGF- 1 may first be
required to suppress the strong bacteria-driven inflamma-
tory response before the cell contact–mediated pathway
can function.
Taken together, our studies do not support the view that
secreted or cell surface–associated TGF- 1 contribute
significantly to the in vitro suppressive functions of
CD4 CD25  T cells. Although CD4 CD25  T cells from
Smad3 /  mice, which cannot respond to TGF- 1-
induced growth inhibition, appeared to function as effi-
ciently as CD4 CD25  T cells from WT mice, it remains
possible that TGF- 1 could play a role in the induction of
CD4 CD25  suppressor activity. Such a stimulatory effect
on CD4 CD25  suppressor activity would function in a
Smad3-independent fashion. Resting CD4 CD25  T cells
selectively express high levels of mRNA for Tgif, a tran-
scriptional corepressor that suppresses TGF- 1–induced
transcription (44, 45). CD4 CD25  suppressor T cells may
therefore use unique signaling pathways to resist the tradi-
tional downregulatory effects of TGF- 1 and somehow
permit TGF- 1 stimulatory effects. Lastly, a number of
studies have suggested that TGF- 1 may play a critical role
in the development of suppressor function in CD4 CD25 
T cells. Yamagiwa et al. (46) have demonstrated culture of
human CD4 CD45RA RO  T cells in the presence of al-
logeneic stimulators and TGF- 1 resulted in the develop-
ment of a population of potent suppressors that inhibit the
induction of CD8  cytotoxic effector cells. Although the
induction of suppressor cells from CD45RA  population244 CD4 CD25  Regulatory T Cells and TGF- 
also required the presence of a very small number of ( 1%)
of CD4 CD25  T cells, it is highly unlikely that the sup-
pressors generated in these cultures were derived from this
small number of precursors. Zeller et al. (47) generated a
population of murine alloantigen-specific suppressor T cells
by coculture of CD4  responder cells with alloantigen-
bearing stimulators in the presence of both IL-10 and
TGF- 1 T cells primed with alloantigen under these con-
ditions readily suppressed both primary and secondary
MLR cultures and were also markedly impaired in their
ability to induce GVHD responses upon adoptive transfer
to MHC class II disparate recipients. Although the relation-
ship of these suppressor T cells to CD4 CD25  T cells re-
mains unclear, the recent studies of Barrat et al. (48) clearly
demonstrate that potent IL-10–producing suppressor T
cells can be generated by culture of CD4 CD25  T cells
with antigen and the combination of vitamin D3 and
dexamethasone. Thus, while most studies have focused on
the role of TGF- 1 as an effector suppressor cytokine,
TGF- 1 may also play an equally important role in the
induction and maintenance of suppressor T cells from
CD4 CD25  T precursor cells both in vitro and in vivo.
Nonetheless, our current study demonstrates for the first
time that CD4 CD25  regulatory T cells can mediate con-
tact-dependent and antigen-nonspecific suppression in the
complete absence of suppressor-derived TGF- 1 produc-
tion and functional TGF- 1 responsiveness by target T cells.
Submitted: 15 April 2002
Accepted: 5 June 2002
References
1. Bach, J.F. 1995. Organ-specific autoimmunity. Immunol. To-
day. 16:353–355.
2. King, C., and N. Sarvetnick. 1997. Organ-specific autoim-
munity. Curr. Opin. Immunol. 9:863–871.
3. Moller, G. 1996. Dominant immunological tolerance. Immu-
nol. Rev. 149:1–17.
4. Shevach, E.M. 2000. Regulatory T cells in autoimmmunity.
Annu. Rev. Immunol. 18:423–449.
5. Sakaguchi, S. 2000. Regulatory T cells: key controllers of im-
munologic self-tolerance. Cell. 101:455–458.
6. Shevach, E.M. 2000. Suppressor T cells: rebirth, function and
homeostasis. Curr. Biol. 10:R572–R575.
7. Salomon, B., D.J. Lenschow, L. Rhee, N. Ashourian, B.
Singh, A. Sharpe, and J.A. Bluestone. 2000. B7/CD28
costimulation is essential for the homeostasis of the
CD4 CD25  immunoregulatory T cells that control au-
toimmune diabetes. Immunity. 12:431–440.
8. Thornton, A.M., and E.M. Shevach. 1998. CD4 CD25 
immunoregulatory T cells suppress polyclonal T cell activa-
tion in vitro by inhibiting interleukin 2 production. J. Exp.
Med. 188:287–296.
9. Piccirillo, C.A., and E.M. Shevach. 2001. Cutting edge: con-
trol of CD8  T cell activation by CD4 CD25  immunoreg-
ulatory cells. J. Immunol. 167:1137–1140.
10. Suri-Payer, E., and H. Cantor. 2001. Differential cytokine
requirements for regulation of autoimmune gastritis and coli-
tis by CD4 CD25  T cells. J. Autoimmun. 16:115–123.
11. Dang, H., A.G. Geiser, J.J. Letterio, T. Nakabayashi, L.
Kong, G. Fernandes, and N. Talal. 1995. SLE-like autoanti-
bodies and Sjogren’s syndrome-like lymphoproliferation in
TGF-  knockout mice. J. Immunol. 155:3205–3212.
12. Geiser, A.G., J.J. Letterio, A.B. Kulkarni, S. Karlsson, A.B.
Roberts, and M.B. Sporn. 1993. Transforming growth factor
  1 (TGF- 1) controls expression of major histocompatibil-
ity genes in the post-natal mouse: aberrant histocompatibility
antigen expression in the pathogenesis of the TGF- 1 null
mouse phenotype. Proc. Natl. Acad. Sci. USA. 90:9944–9948.
13. Christ, M., N.L. McCartney-Francis, A.B. Kulkarni, J.M.
Ward, D.E. Mizel, C.L. Mackall, R.E. Gress, K.L. Hines, H.
Tian, and S. Karlsson. 1994. Immune dysregulation in TGF-
 1-deficient mice. J. Immunol. 153:1936–1946.
14. Letterio, J.J. 2000. Murine models define the role of TGF- 
as a master regulator of immune cell function. Cytokine &
Growth Factor Rev. 11:81–87.
15. Letterio, J.J., and A.B. Kulkarni. 1997. The transforming
growth factor-b1 knockout mouse. In Cytokine Knockout
Mice. S. Durum and K. Muegge, editors. Humana, Totow,
NJ. 369–400.
16. Gorelik, L., and R.A. Flavell. 2000. Abrogation of TGF- 
signaling in T cells leads to spontaneous T cell differentiation
and autoimmune disease. Immunity. 12:171–181.
17. Lucas, P.J., S.J. Kim, S.J. Melby, and R.E. Gress. 2000. Dis-
ruption of T cell hemostasis in mice expressing a T cell-spe-
cific dominant negative transforming growth factor   II re-
ceptor. J. Exp. Med. 191:1187–1196.
18. Yang, X., J.J. Letterio, R.J. Lechleider, L. Chen, R. Hay-
man, H. Gu, A.B. Roberts, and C. Deng. 1999. Targeted
disruption of SMAD3 results in impaired mucosal immunity
and diminished T cell responsiveness to TGF- . EMBO J.
18:1280–1291.
19. Gorelick, L., and R.A. Flavell. 2002. Transforming growth
factor-  in T cell biology. Nat. Rev. Immunol. 2:46–53.
20. Read, S., V. Malmstrom, and F. Powrie. 2000. Cytotoxic T
lymphocyte-associated antigen 4 plays an essential role in the
function of CD25 CD4  regulatory cells that control intesti-
nal inflammation. J. Exp. Med. 192:295–302.
21. Seddon, B., and D. Mason. 1999. Regulatory T cells in the
control of autoimmunity: the essential role of transforming
growth factor   and interleukin 4 in the prevention of au-
toimmune thyroiditis in rats by peripheral CD4  CD45RC 
cells and CD4 CD8  thymocytes. J. Exp. Med. 189:279–288.
22. Read, S., S. Mauze, C. Asseman, A. Bean, R. Coffman, and
F. Powrie. 1998. CD38  CD45RBlow CD4  T cells: a popu-
lation of T cells with immune regulatory activities in vitro.
Eur. J. Immunol. 28:3435–3447.
23. Takahashi, T., Y. Kuniyasu, M. Toda, N. Sakaguchi, M.
Itoh, M. Iwata, J. Shimizu, and S. Sakaguchi. 1998. Immu-
nologic self-tolerance maintained by CD25 CD4  naturally
anergic and suppressive T cells: induction of autoimmune
disease by breaking their anergic/suppressive state. Int. Immu-
nol. 10:1969–1980.
24. Stephens, L.A., C. Mottet, D. Mason, and F. Powrie. 2001.
Human CD4 CD25  thymocytes and peripheral T cells
have immune suppressive activity in vitro. Eur. J. Immunol.
31:1247–1254.
25. Taams, L.S., J. Smith, M.H. Rustin, M. Salmon, L.W.
Poulter, and A.N. Akbar. 2001. Human anergic/suppressive
CD4 CD25  T cells: a highly differentiated and apoptosis-
prone population. Eur. J. Immunol. 31:1122–1131.
26. Jonuleit, H., E. Schmitt, M. Stassen, A. Tuettenberg, J.245 Piccirillo et al.
Knop, and A.H. Enk. 2001. Identification and functional
characterization of human CD4 CD25  T cells with regula-
tory properties isolated from peripheral blood. J. Exp. Med.
193:1285–1294.
27. Dieckmann, D., H. Plottner, S. Berchtold, T. Berger, and G.
Schuler. 2001. Ex vivo isolation and characterization of
CD4 CD25  T cells with regulatory properties from human
blood. J. Exp. Med. 193:1303–1310.
28. Ng, W.F., P.J. Duggan, F. Ponchel, G. Matarese, G. Lom-
bardi, A.D. Edwards, J.D. Isaacs, and R.I. Lechler. 2001.
Human CD4 CD25  cells: a naturally occurring population
of regulatory T cells. Blood. 98:2736–2744.
29. Levings, M.K., R. Sangregorio, and M.G. Roncarolo. 2001.
Human CD25 CD4  T regulatory cells suppress naive and
memory T cell proliferation and can be expanded in vitro
without loss of function. J. Exp. Med. 193:1295–1302.
30. Nakamura, K., A. Kitani, and W. Strober. 2001. Cell con-
tact-dependent immunosuppression by CD4 CD25  regula-
tory T cells is mediated by cell surface-bound transforming
growth factor  . J. Exp. Med. 194:629–644.
31. Kulkarni, A.B., C.G. Huh, D. Becker, A. Geiser, M. Lyght,
K.C. Flanders, A.B. Roberts, M.B. Sporn, J.M. Ward, and S.
Karlsson. 1993. Transforming growth factor   1 null muta-
tion in mice causes excessive inflammatory response and early
death. Proc. Natl. Acad. Sci. USA. 90:770–774.
32. Coligan, J. 1999. Current Protocols in Immunology. J. Coli-
gan, editor. John Wiley & Sons, Inc., New York. 4–9.
33. McHugh, R.S., E.M. Shevach, D.H. Margulies, and K. Nat-
arajan. 2001. A T cell receptor transgenic model of severe,
spontaneous organ-specific autoimmunity. Eur. J. Immunol.
31:2094–2103.
34. Thornton, A.M., and E.M. Shevach. 2000. Suppressor effec-
tor function of CD4 CD25  immunoregulatory T cells is
antigen nonspecific. J. Immunol. 164:183–190.
35. Datto, M.B., J.P. Frederick, L. Pan, A.J. Borton, Y. Zhuang,
and X.F. Wang. 1999. Targeted disruption of Smad3 reveals
an essential role in transforming growth factor  -mediated
signal transduction. Mol. Cell. Biol. 19:2495–2504.
36. Suri-Payer, E., A. Amar, A.M. Thornton, and E.M. Shevach.
1998. CD4 CD25  T cells inhibit both the induction and
effector function of autoreactive T cells and represent a
unique lineage of immunoregulatory cells. J. Immunol. 160:
1212–1218.
37. Fowell, D., F. Powrie, A. Saoudi, B. Seddon, V. Heath, and
D. Mason. 1995. The role of subsets of CD4  T cells in au-
toimmunity. Ciba Found. Symp. 195:173–182.
38. Katz, J.D., C. Benoist, and D. Mathis. 1995. T-helper cell
subsets in insulin-dependent diabetes. Science. 268:1185–
1188.
39. Shevach, E.M., R.S. McHugh, C.A. Piccirillo, and A.M.
Thornton. 2001. Control of T-cell activation by CD4 
CD25  suppressor T cells. Immunol. Rev. 182:58–67.
40. Prud’homme, G.J., and C.A. Piccirillo. 2000. The inhibitory
effects of transforming growth factor- -1 (TGF- 1) in au-
toimmune diseases. J. Autoimmun. 14:23–42.
41. Suri-Payer, E., and H. Cantor. 2001. Differential cytokine
requirements for regulation of autoimmune gastritis and coli-
tis by CD4  CD25  T cells. J. Autoimmun. 16:115–123.
42. Singh, B., S. Read, C. Asseman, V. Malmstrom, C. Mottet,
L.A. Stephens, R. Stepankova, H. Tlaskalova, and F. Powrie.
2001. Control of intestinal inflammation by regulatory T
cells. Immunol. Rev. 182:190–200.
43. Groux, H., and F. Powrie. 1999. Regulatory T cells and in-
flammatory bowel disease. Immunol. Today. 20:442–446.
44. McHugh, R.S., M.J. Whitters, C.A. Piccirillo, D.A. Young,
E.M. Shevach, M. Collins, and M.C. Byrne. 2002. CD4 
CD25  immunoregulatory T cells: gene expression analysis
reveals a functional role for the glucocorticoid-induced TNF
receptor. Immunity. 16:311–323.
45. Gavin, M.A., S.R. Clarke, E. Negrou, A. Gallegos, and A.
Rudensky. 2001. Homeostasis and anergy of CD4 CD25 
suppressor T cells in vivo. Nat. Immunol. 3:33–41.
46. Yamagiwa, S., J.D. Gray, S. Hashimoto, and D.A. Horwitz.
2001. A role for TGF-  in the generation and expansion of
CD4 CD25  regulatory T cells from human peripheral
blood. J. Immunol. 166:7282–7289.
47. Zeller, J.C., A. Panoskaltsis-Mortari, W.J. Murphy, F.W.
Ruscetti, S. Narula, M.G. Roncarolo, and B.R. Blazar. 1999.
Induction of CD4  T cell alloantigen-specific hyporespon-
siveness by IL-10 and TGF- . J. Immunol. 163:3684–3691.
48. Barrat, F.J., D.J. Cua, A. Boonstra, D.F. Richards, C. Crain,
H.F. Savelkoul, R. de Waal-Malefyt, R.L. Coffman, C.M.
Hawrylowicz, and A. O’Garra. 2002. In vitro generation of
interleukin 10-producing regulatory CD4  T cells is induced
by immunosuppressive drugs and inhibited by T helper type
1 (Th1)- and Th2-inducing cytokines. J. Exp. Med. 195:603–
616.